Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Treatment of lycorine on SCID mice model with human APL cells

J. Liu a, Y. Li a, L.J. Tang a, G.P. Zhang b, W.X. Hu a,∗

a Molecular Biology Research Center, School of Biological Science and Technology, Central South University, 110 Xiangya Road, Changsha, Hunan 410078, PR China
b Department of Hematology, Xiangya Hospital, Central South University, Changsha 410078, PR China

Received 20 October 2006; accepted 12 January 2007
Available online 12 February 2007

Abstract

In our previous study, lycorine, a natural alkaloid extracted from Amaryllidaceae, exhibited anti-leukemia effects in vitro. To determine whether lycorine has an anti-tumor effect in vivo, a series of experiments were carried out in this study. HL-60 cells (5 × 10^6) were inoculated i.v. into severe combined immuno-deficiency (SCID) mice after these mice had been irradiated (total body receiving 200 cGy X irradiation). Treatment was given once a day from day 2 to 6, and from day 14 to 18. Lycorine (5 or 10 mg/kg/day i.p.) was found to decrease the percentages of immature granular leukocytes and of monocytes among the peripheral blood cells, and the mean survival time of both lycorine-treated groups was longer than that of the control group. Compared with the asynchronous and cytosine arabinoside- (Ara-C) treated (20 mg/kg/day i.p.) group, treatment with lycorine was more effective. Lycorine was also found to alleviate the infiltration of tumor cells into the liver, bone, and marrow. When SCID mice inoculated with HL-60 cells were then treated with lycorine, no severe adverse effects were observed. This study revealed that lycorine, when tested in the human leukemia xenograft models, appears to exhibit anti-tumor activity in vivo and is a useful therapy against acute promyelocytic leukemia.

© 2007 Elsevier Masson SAS. All rights reserved.

Keywords: Lycorine; Leukemia; HL-60 cells; Xenograft

1. Introduction

Leukemia is considered one of the most life-threatening cancers today. In 2001, approximately 21 500 deaths (12 100 males; 9500 females) in the United States were attributed to leukemia. Acute promyelocytic leukemia (APL) is a common type of leukemia. At present, chemotherapeutic agents are extremely useful in treating leukemia [1–3]. Finding novel anti-tumor chemotherapeutic medicine derived from natural materials has become an important research objective and has been the aim of new drug designs [4]. Many natural compounds have already been found to exhibit significant anti-tumor effects. Tea polyphenols can induce HL-60 cells apoptosis [5]. G2-M arrest and antimitotic activity can mediate by casticin [6].

Albatrellus confluens has the ability to inhibit the growth of tumor cells by the induction of apoptosis [7]. Extracts from Narcissus tazetta var. chinensis strongly decreased the survival rate of many tumor cell lines [8]. Lycorine, a natural alkaloid extracted from Amaryllidaceae, has shown various pharmacological and microbiological effects. Researchers had revealed that lycorine can inhibit protein synthesis in eukaryotic cells [9], and acetylcholinesterase activity [10]. In the presence of calprotectin, lycorine was shown to inhibit protein synthesis and cell apoptosis in MM46 cells [11]. Lycorine was found a potent antiviral activity against Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) in recent report [12]. Lycorine could effectively arrest the cell cycle at the G2/M phase and induce apoptosis in HL-60 cells [13]. After treatment of human multiple myeloma cell line KM3 with lycorine, typical apoptotic events could be observed, and the results also showed that lycorine was able to block the KM3 cell cycle at G0/G1 phase through the down-regulation of both cyclin D1 and CDK4 [14]. In our
previous study, we focused on the significant anti-tumor effects of lycorine. However, the anti-tumor effect of lycorine in vivo remains unknown. Therefore, it is important to determine the therapeutic effect of lycorine on leukemia in an animal model. SCID mice are widely used in cancer research especially in anti-leukemia research and can provide a system model to study the biology of human leukemias and explore the efficacy of novel leukemia research and can provide a system model to study the biology of human leukemias and explore the efficacy of novel leukemia treatment programs [15]. Previously, a leukemia model of SCID mice was successfully set up, where human leukemia cells could be detected in the bone marrow, spleen, and lymph nodes of SCID mice in a pattern resembling that of human acute leukemia [16,17]. In this study, the effect of lycorine on APL in vivo was evaluated in a human leukemia xenograft model (i.e., SCID mice inoculated with HL-60 cells), although such a model would not completely reflect the situation in patients with leukemia.

2. Materials and methods

2.1. Cell culture

The human APL cell line HL-60 was purchased from the American Type Culture Collection. Cells were routinely cultured in RPMI 1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen), 100 kU/L benzylpenicillin, and 100 mg/L streptomycin at 37 °C in a humidified atmosphere with 5% CO2. Cells were split at a 1:5 dilution every 2 to 3 days.

2.2. Drugs and chemicals

Lycorine (Latoxan, France) was dissolved at 0.03 M in dimethyl sulfoxide (DMSO; Sigma) as a stock solution and then diluted in normal saline just prior to usage. The asynchronous and cytosine arabinoside (Ara-C) injection (Shanghai Hualian Pharmaceutical Co., Ltd., China) was diluted in saline just prior to usage.

2.3. Animals

Female BALB/c SCID mice (3–5 weeks old) were obtained from the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences and were maintained in a specific pathogen-free facility at the Lab Animal Center of Central South University. The mice were allowed to adjust to their new environment for 1 week. Twenty-four hours after the mice were irradiated (total body with 200 cGy x irradiation) to diminish the natural killer cell activity, the mice were inoculated with HL-60 cells (5 x 10

2

6

) i.v. via the tail vein on day 1. The mice bearing APL cells were randomized (5 per group) into 1 of 4 groups and treated according to the following protocols: (a) control (normal saline i.p.); (b) lycorine (5 mg/kg/day i.p.); (c) lycorine (10 mg/kg/day i.p.); and (d) Ara-C (20 mg/kg/day i.p.). Treatment was given once a day from day 2 to 6, and from day 14 to 18.

2.4. Peripheral blood cells

After the SCID mice were inoculated i.v. with HL-60 cells and treated with drugs, tail blood samples were taken from these mice every 7 days (day 14, 21, and 28). These samples were then smeared onto glass microscope slides and stained using Wright’s stain. The percentages of immature granular leukocytes and of monocytes among the peripheral blood cells were monitored in these mice [18,19].

2.5. Survival time

The survival time results were recorded and expressed as the mean survival time percentage of the treated group divided by that of the control group (treated vs. control, T/C, %). The increased life span (ILS) was expressed as the mean survival time of the treated group minus that of the control group over the mean survival time of the control group [20]. With National Cancer Institute (NCI) criteria, T/C exceeding 125% and ILS exceeding 25% indicate that the drug has significant anti-tumor activity [21].

2.6. Weight and histopathological analysis

To evaluate the toxicity and side-effect of lycorine on mice, the weight of mice was monitored at day 0, 14, 21, and 28 as described previously [22]. All SCID mice bearing human leukemia were sacrificed painlessly when mice were close to death. Bone marrow samples from the thighbone of the mice were obtained, flushed with saline, smeared onto glass microscope slides, and stained using Wright’s stain. Tissues from excised organs, including the liver, spleen, and bone, were fixed in 4% formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin to check for the presence or absence of tumor cells under the microscope.

2.7. Statistical analysis

Data were analyzed using the paired Student’s t-test, and a probability score of P < 0.05 was considered statistically significant.

| Group          | d 14 (%) | d 21 (%) | d 28 (%) |
|----------------|----------|----------|----------|
| Control        | 44.95 ± 8.75 | 37.33 ± 5.94 | 31.80 ± 10.45 |
| Lycorine (5 mg/kg/day) | 37.62 ± 8.23 | 29.42 ± 12.15 | 23.60 ± 8.35 |
| Lycorine (10 mg/kg/day) | 22.49 ± 9.53* | 26.90 ± 3.36* | 21.17 ± 6.90 |

(Compared with the contemporaneous control group, *P < 0.05. Compared with the contemporaneous lycorine group (5 mg/kg/day), #P < 0.05. Every seven days (day 14, 21, and 28) after treatment, tail blood samples were taken from mice and samples were smeared onto glass microscope slides and stained with Wright’s stain. Then the percentages of immature granular leukocytes and of monocytes of the mice were monitored among the peripheral blood cells after the mice had been inoculated i.v. with HL-60 cells.
3. Results

3.1. Lycorine decreased the percentages of immature granular leukocytes and of monocytes among the peripheral blood cells

After treatment, the percentages of immature granular leukocytes and of monocytes among the peripheral blood cells of the control group were comparatively high, whereas the percentages of immature granular leukocytes and of monocytes of the experiment groups were decreased. When compared with the control group at day 14 and day 21, the percentages of immature granular leukocytes and monocytes among the peripheral blood cells in the high dosage of lycorine (10 mg/kg/day) group was significant decreased ($P < 0.05$). We also observed that the high dosage of lycorine (10 mg/kg/day) was more effective than that of the low dosage of lycorine (5 mg/kg/day) at day 14 (Table 1). Furthermore, treatment with either the high or low dosage of lycorine was shown to be more effective than treatment with Ara-C (20 mg/kg/day) (data not shown).

3.2. Lycorine prolonged the mean survival time of SCID leukemia xenograft models

There was no significant difference between the mean survival time of the control group (41.6 ± 7.3 days; range: 34–49) and that of the Ara-C treated group (42.8 ± 9.8 days; range: 30–52). In comparison, the mean survival time of the group receiving the low dosage of lycorine (5 mg/kg/day) was 54.2 ± 13.8 days (range: 38–71 days); the ILS and T/C values were 30.0% and 130%, respectively. The mean survival time of the group receiving the high dosage of lycorine (10 mg/kg/day) was 55.8 ± 10.2 days (range: 39–64 days); the ILS and T/C values were 34.0% and 134%, respectively. The mean survival time of the two lycorine-treated groups compared with the control group or the Ara-C treated group, $P < 0.05$ (Table 2, Fig. 1).

3.3. Lycorine could alleviate the infiltration of tumor cells into tissues

The anti-tumor activity of lycorine in vivo was further investigated using histopathological analysis. Typical leukemia cells were observed in the marrow smear of the control group (Fig. 2A). The marrow cavity of the sternal bone in the control group changed to sawtooth (Fig. 2C), whereas the marrow cavity of the sternal bone in the lycorine-treated group was normal (Fig. 2D). Big abnormality cells were observed in the sides parenchyma of bone (Fig. 2E) and in the liver of the control group (Fig. 2G). All of these findings indicated that tumor cells were easily and widely found in the liver, bone, and marrow of the mice in the control groups, whereas fewer tumor cells were detected in these same tissues of the mice belonging to the lycorine-treated groups.

3.4. Lycorine had no significant effect on the weight of SCID mice

In addition, no severe adverse effects, such as weight loss, were observed in the mice receiving lycorine (Table 3). The mean weight of SCID mice in the control group from day 0 to day 28 was 16.2 ± 2.8 g, 16.7 ± 1.8 g, 16.7 ± 0.7 g and 17.8 ± 1.7 g, respectively, two SCID mice in this group developed abdominal lump. Meanwhile, the mean weight of the group receiving the low dosage of lycorine (5 mg/kg/day) was 17.8 ± 1.5 g, 16.6 ± 0.7 g, 17.2 ± 0.3 g and 17.7 ± 1.7 g, respectively. The mean weight of the group receiving the high dosage of lycorine (10 mg/kg/day) was 17.1 ± 0.8 g, 16.5 ± 1.3 g, 17.0 ± 0.8 g and 17.1 ± 1.8 g, respectively. At

---

### Table 2

| Groups | No. of mice | Dosage and route (i.p.) | Survival days | ILS (%) | T/C (%) |
|--------|-------------|-------------------------|---------------|--------|--------|
|        |             |                         | Mean ± SD     | Range  |        |
| Control | 5           | Normal saline           | 41.6 ± 7.3    | 34–49  |        |
| Lycorine| 5           | 5 mg/kg/day             | 54.2 ± 13.8** | 38–71  | 30.0   | 130    |
| Lycorine| 5           | 10 mg/kg/day            | 55.8 ± 10.2** | 39–64  | 34.0   | 134    |
| Ara-C  | 5           | 20 mg/kg/day            | 42.8 ± 9.8    | 30–52  | 3.0    | 103    |

Female BALB/c SCID mice (3–5 weeks old) were injected i.v. with $5 \times 10^6$ HL-60 cells. Treatment of lycorine or Ara-C was started 1 day after the HL-60 cell injection. T/C, treated vs. control; ILS, increased life span. *$P = 0.024$, compared with control group; **$P = 0.011$, compared with the Ara-C treated group; ***$P = 0.007$, compared with control group; ****$P = 0.002$, compared with the Ara-C treated group.

---

Female BALB/c SCID mice (3–5 weeks old) were injected i.v. with $5 \times 10^6$ HL-60 cells. Treatment of lycorine or Ara-C was started 1 day after the HL-60 cell injection. T/C, treated vs. control; ILS, increased life span. The survival time of SCID mice after i.v. injection with $5 \times 10^6$ HL-60 cells on day 1. Mice treated with lycorine survived longer than controls and the Ara-C treated group ($P < 0.05$).
Fig. 2. Histopathological analysis of tissues from SCID mice bearing HL-60 cells. Marrow from the thighbone of the mice was obtained, and samples were smeared onto glass microscope slides and stained with Wright’s stain. Tissues from the liver and bone were fixed in 4% formaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. A: marrow of control, typical leukemia cells could be seen, ×1000; B: marrow of lycorine- (10 mg/kg/day) treated group, ×1000; C: bone of control, the marrow cavity of the sternal bone changed to sawtooth (arrows), ×150; D: bone of lycorine- (10 mg/kg/day) treated group, ×150; E: sides parenchyma of bone in the control group, leukemia cells infiltrate (arrows), ×600; F: sides parenchyma of bone in lycorine- (10 mg/kg/day) treated group, ×600; G: liver of control, leukemia cells infiltrate the liver (arrows) ×600; and H: liver of lycorine- (10 mg/kg/day) treated group, ×600.
Female BALB/c SCID mice (3–5 weeks old) were injected i.v. with 5 × 10⁶ HL-60 cells. The mice were weighed at day 0, day 14, day 21 and day 28.

Table 3
Effect of lycorine on weight of SCID mice inoculated with HL-60 cells

| Groups       | No. of mice | Dosage and route (i.p.) | Weight of SCID mice (Mean ± SD) (g) |
|--------------|-------------|-------------------------|-----------------------------------|
| Control      | 5           | Normal saline           | d0 16.2 ± 2.8 d14 16.7 ± 1.8 d21 16.7 ± 0.7 d28 17.8 ± 1.7 |
| Lycorine     | 5           | 5 mg/kg/day             | d0 17.8 ± 1.5 d14 16.6 ± 0.7 d21 17.2 ± 0.3 d28 17.7 ± 1.7 |
| Lycorine     | 5           | 10 mg/kg/day            | d0 17.1 ± 0.8 d14 16.5 ± 1.3 d21 17.0 ± 0.8 d28 17.1 ± 1.8 |
| Ara-C        | 5           | 20 mg/kg/day            | d0 15.5 ± 2.2 d14 15.1 ± 1.8 d21 15.0 ± 1.8 d28 14.7 ± 2.4 |

On day 14 and day 21 the weight of lycorine treated mice decreased slightly, but at day 28 this phenomena didn’t exist.

4. Discussion

Our observation of in vivo anti-leukemia effect of lycorine extends our previous in vitro results with human leukemic cells. SCID mice transplanted with human APL cells displayed a high degree of engraftment and proliferation of human tumor cells among the peripheral blood cells [19]. The percentages of immature granular leukocytes and of monocytes among the peripheral blood cells of mice treated with lycorine were decreased compared with those of the control group (P < 0.05), which showed that lycorine not only inhibits the proliferation but also induces the death of tumor cells effectively [13,14]. When compared with the control group, the ILS values of the groups receiving a low dosage (5 mg/kg/day) and a high dosage (10 mg/kg/day) of lycorine were 30.0% and 34%, respectively, indicating that lycorine had anti-tumor activity [21]. The mean survival time of both lycorine-treated groups was longer than that of the Ara-C treated group, which suggested that lycorine was more effective than Ara-C. The SCID mice that were inoculated with HL-60 cells in the control group developed an infiltration of tumor cells in the liver and in the bone marrow, and peripheral blasts [17], whereas lycorine could alleviate the infiltration of tumor cells and no severe adverse effects were observed with the low or high dosage of lycorine.

During the early period after treatment (before day 28), the anti-tumor effect of the high dosage (10 mg/kg/day) of lycorine was better than that of the low dosage (5 mg/kg/day), but the mean survival time was not significantly improved when the dosage of lycorine was increased. The treatment schedules were carried out only with early treatment [23], which could not eliminate the tumor cells fully. For the too complex dysfunction of cancer cells, it will be important to evaluate the activity further in combination with other therapeutic.

We have shown that lycorine is a potent anti-tumor compound. In addition to our previous study that showed lycorine to have a significant anti-tumor effect in vitro [13,14], this present study demonstrates that lycorine exhibits potent anti-tumor activity in an HL-60 xenograft model. Although the SCID mice model used in this study has limitations and does not completely reflect the situation in patients with acute leukemia, these results suggest this treatment is a useful therapy against APL.

Acknowledgements

This work was supported with the grants from the National Natural Science Foundation of China (Nos. 30270750, 30300406, 30400529 and 30500269).

References

[1] Bieker R, Lerchenmuller C, Wehmeijer J, Serve HL, Mesters RM, Buchner T, et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep 2003;10:915–20.

[2] Chow LM, Chui CH, Tang JC, Teo IT, Lau FY, Cheng GY, et al. Gleditsia sinensis fruit extract is a potential chemotherapeutic agent in chronic and acute myelogenous leukemia. Oncol Rep 2003;10:1601–7.

[3] Servida F, Soligo D, Delia D, Henderson C, Brancolini C, Lombardi L, et al. Sensitivity of human multiple myelomas and myeloid leukaemias to the proteasome inhibitor I. Leukaemia 2005;19:2324–31.

[4] Chanda SK, Caldwell JS. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 2003;8:168–74.

[5] Zhao Y, Cao J, Ma H, Liu JW. Apoptosis induced by tea polyphenols in HL-60 cells. Cancer Lett 1997;121:163–7.

[6] Kobayakawa J, Sato-Nishimoria F, Moriyasu M, Matsukawa Y. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Vitex Fructus (Vitex rotundifolia Linne fil.). Cancer Lett 2004;208:59–64.

[7] Ye M, Liu JK, Lu ZX, Zhao Y, Liu SF, Li LL, et al. Grifolin, a potential antitumor natural product from the mushroom Albatrellus confluens, inhibits tumor cell growth by inducing apoptosis in vitro. FEBS Lett 2005;579:3437–43.

[8] Liu J, Li Y, Ren W, Hu WX. Apoptosis of HL-60 cells induced by extracts from Narcissus tazetta var. chinsensis. Cancer Lett 2006;242:133–40.

[9] Jimenez A, Santos A, Alonso G, Vazquez D. Inhibitors of protein synthesis in eukaryotic cells. Comparative effects of some amarylides. Biochim Biophys Acta 1976;425:342–8.

[10] Hohmann J, Forgo P, Molnar J, Wolfard K, Molnar A, Thalhammer T, et al. Antiproliferative amarylides isolated from the bulbs of Sprekelia formosissima and Hymenocallis x festalis. Planta Med 2002;68:433–4.

[11] Elgorashi EE, Stafford GI, Van Staden J. Acetylcholinesterase enzyme inhibitory effects of amarylides. Planta Med 2004;70:260–2.

[12] Li SY, Chen C, Zhang HQ, Gao HY, Wang H, Wang L, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 2005;7:18–23.

[13] Liu J, Hu WX, He LF, Ye M, Li Y. Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS Lett 2004;578:245–50.

[14] Li Y, Liu J, Tang LJ, Shi YW, Ren W, Hu WX. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest. Oncol Rep 2007;17:577–84.
[15] Uckun FM. Severe combined immunodeficient mouse models of human leukemia. Blood 1996;88(4):1135–45.
[16] Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, et al. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 1989;246:1597–600.
[17] Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia 1999;13:629–33.
[18] Na XD, He Q, Jiang DZ. Effect of a novel aminosteroid on animal model of murine myelomonocytic leukemia. Hunan Yi Ke Da Xue Xue Bao 2000;25:12–4.
[19] Henschler R, Gottig S, Junghahn I, Bug G, Seifried E, Muller AM, et al. Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers. Leuk Res 2005;29:1191–9.
[20] Gourdeau H, Bibeau L, Ouellet F, Casteau D, Bernier L, Bowlin T. Comparative study of a novel nucleoside analogue (Troxytix, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 2001;47:236–40.
[21] Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC. Human tumor xenograft models in NCI drug development. In: Teicher B, editor. Totowa, NJ: Humana Press; 1995. p. 101.
[22] Murray S, Schell K, McCarthy DO, Albertini MR. Tumor growth, weight loss and cytokines in SCID mice. Cancer Lett 1997;111:111–5.
[23] Tomkinson B, Bendele R, Giles Fl, Brown E, Gray A, Hart K, et al. OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leuk Res 2003;27:1039–50.